Malta - English - Medicines Authority

pfizer hellas s.a. 243 messoghion ave., neo psychiko 15451, athens, greece - tick, borne encephalitis, virus - suspension for injection in pre-filled syringe - tick-borne encephalitis virus 1,2 0.5 ml - vaccines

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

imported (korea) - japanese encephalitis virus - solution for injection

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

imported (korea) - japanese encephalitis virus - solution for injection

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

imported (korea) - japanese encephalitis virus - solution for injection

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - japanese encephalitis virus -

New Zealand - English - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - hepatitis a vaccine 50 u/ml - suspension for injection - 50 u/ml - active: hepatitis a vaccine 50 u/ml excipient: aluminium as amorphous aluminium hydroxyphosphate sulphate borax sodium chloride water for injection - vaqta is indicated for active pre-exposure prophylaxis against disease caused by hepatitis a virus. primary immunisation should be given at least 2 weeks prior to expected exposure to hav. vaccination is recommended in children 12 months of age and older, adolescents, and adults who are at risk of contracting or spreading infection or who are at risk of life-threatening disease if infected, including but not limited to: · travellers to endemic or outbreak areas · frequently affected communities - members residing in any community with one or more recorded outbreaks within the last five years · daycare - children and staff of daycare centres as well as their parents, siblings, and other contacts · military personnel prior to departure for endemic or outbreak areas · persons for whom hepatitis a is an occupational hazard - health-care workers - staff and residents of orphanages, chronic care hospitals and mental health care facilities - sewage workers · haemophiliacs and other recipients of therapeutic blood products · persons who test positive for hepatitis c virus and have diagnosed liver disease · food handlers · consumers of high-risk foods e.g. raw shellfish · persons at increased risk of the disease due to their sexual practices - homosexually-active males - persons who repeatedly contract sexually transmitted diseases · human immunodeficiency virus (hiv)-infected adults · users of illicit injectable drugs vaqta will not prevent hepatitis caused by infectious agents other than hepatitis a virus.

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - yellow fever virus, quantity: 1000 pfu e.1000 mouse ld50 - injection, powder for - excipient ingredients: calcium chloride dihydrate; magnesium sulfate heptahydrate; histidine hydrochloride; sodium chloride; dibasic sodium phosphate dihydrate; alanine; sorbitol; potassium chloride; lactose monohydrate; monobasic potassium phosphate; sodium hydroxide - prevention of yellow fever. vaccination is recommended for:,? every individual aged 9 months and over living or travelling through an endemic area with a current or periodic risk of yellow fever transmission. ? non-vaccinated individual moving from an endemic area with a current or periodic risk of yellow fever transmission to a potentially receptive non-endemic area with a current or periodic risk of yellow fever transmission. ? laboratory workers handling potentially infectious materials. in order to be officially recognised, the yellow fever vaccination must be administered in an approved vaccination centre and registered on an international certificate. the validity period of the certificate is established according to international health regulations recommendations and starts 10 days after primary vaccination and immediately after re-vaccination.

Singapore - English - HSA (Health Sciences Authority)

aenon pharmaceuticals sea pte. ltd. - japanese encephalitis virus strain sa₁₄-14-2 (inactivated) - injection, suspension - 6 μg/0.5 ml - japanese encephalitis virus strain sa₁₄-14-2 (inactivated) 6 μg/0.5 ml

European Union - English - EMA (European Medicines Agency)

gsk vaccines s.r.l. - meningococcal group a, c, w-135 and y conjugate vaccine - immunization, meningitis, meningococcal - bacterial vaccines - prefilled syringe menveo is indicated for active immunisation of adolescents (from 11 years of age) and adults at risk of exposure to neisseria meningitidis groups a, c, w135 and y, to prevent invasive disease. the use of this vaccine should be in accordance with official recommendations. vials menveo is indicated for active immunisation of children (from two years of age), adolescents and adults at risk of exposure to neisseria meningitidis groups a, c, w135 and y, to prevent invasive disease. the use of this vaccine should be in accordance with official recommendations.,

Israel - English - Ministry of Health

pfizer pharmaceuticals israel ltd - encephalitis, tick borne, inactivated, whole virus - suspension for injection - encephalitis, tick borne, inactivated, whole virus 2.4 mcg / 0.5 ml - encephalitis, tick borne, inactivated, whole virus - ticovac 0.5 ml is indicated for the active (prophylactic) immunization of adolescents from 16 years of age and adults against tick-borne encephalitis (tbe).